In light of the continued impact from SARS-CoV-2, the virus responsible for COVID-19, we have seen an increasing demand for assay development services as well as essential reagents. Rapid diagnostic tests are critical tools for screening at-risk populations and managing the spread of the outbreak, and we are actively helping in this fight.
nanoComposix is fully equipped to support new lateral flow assay development projects. Our team of experts can help develop an early stage point of care test from concept to prototype in as little as 4 weeks. Learn more about our Lateral Flow Assay Development capabilities.
nanoComposix can assist in all phases of lateral flow device manufacturing. From R&D to GMP, nanoComposix contract manufacturing department can help produce the material needed to support your product. We support R&D, pilot runs, gap manufacturing and are equipped to produce up to 10 million lateral flow tests each month under our ISO 13485:2016 certified Quality Management System. Contact us for a quote.
White Label Opportunities (OEM)
nanoComposix has extensive experience in the LFA serological space, and has worked with both private corporations and government agencies (e.g. CDC, NIAID, NIH, etc.) to develop lateral flow diagnostics for infectious diseases, such as: cytomegalovirus infection, hepatitis C, hepatitis E, Lyme disease, paragonimiasis, loa loa filariasis, and tuberculosis. We are now completing the development of a serological assay for COVID-19 that measures both the IgM and IgG response in whole blood. nanoComposix has the rights to earmark certain tests for white label distribution. Contact us to learn more.